<DOC>
	<DOCNO>NCT00000978</DOCNO>
	<brief_summary>To determine safety , tolerability , activity zidovudine ( AZT ) zalcitabine ( dideoxycytidine ; ddC ) bloodstream level drug patient AIDS advance AIDS-related complex ( ARC ) . Treatments use AZT alternate ddC evaluate ongoing trial goal reduce toxicity maintain antiviral effect . In addition , AZT ddC may work together way drug take low dose less frequent interval give together . If dos reduce , toxicity associate long-term use one drug may reduce . Combination AZT ddC might reduce likelihood emergence resistant mutant . Recent study indicate reduce sensitivity HIV isolate patient prolonged AZT therapy . Although clinical significance find clear , would indicate combination study important . HIV strain decrease sensitivity AZT still sensitive ddC .</brief_summary>
	<brief_title>A Study Dideoxycytidine Plus Zidovudine Treatment AIDS Advanced AIDS Related Complex ( ARC )</brief_title>
	<detailed_description>Treatments use AZT alternate ddC evaluate ongoing trial goal reduce toxicity maintain antiviral effect . In addition , AZT ddC may work together way drug take low dose less frequent interval give together . If dos reduce , toxicity associate long-term use one drug may reduce . Combination AZT ddC might reduce likelihood emergence resistant mutant . Recent study indicate reduce sensitivity HIV isolate patient prolonged AZT therapy . Although clinical significance find clear , would indicate combination study important . HIV strain decrease sensitivity AZT still sensitive ddC . Patients randomly assign one six treatment group various dose combination AZT ddC . Patients evaluate every week first 10 week biweekly thereafter .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>AIDS-Related Complex</mesh_term>
	<mesh_term>Zalcitabine</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Allowed : Aerosolized pentamidine 300 mg per 4 week . Drugs unlikely cause increase toxicity either study drug unlikely cause peripheral neuropathy . Drugs little nephrotoxicity , hepatotoxicity , cytotoxicity , patient take tolerate well ongoing condition . Acyclovir ( = &lt; 600 mg/day , orally ) . Ketoconazole ( = &lt; 400 mg/day ) . Nystatin ( occasional ) . Acetaminophen nonsteroidal antiinflammatory agent ( low dose ) . Drugs could possibly cause serious additive toxicity coadministered either study drug , unlikely cause peripheral allow use anticipated treatment acute intercurrent illness opportunistic infection . Allowed study drug interruption 21 day per episode , total 42 day study : Acyclovir ( &gt; 600 mg/day ) . Experimental drug include ganciclovir . Fluconazole . Systemic pentamidine . Pyrimethamine . Triple sulfa . Ansamycin . Prolonged continuous use highdose nonsteroidal antiinflammatory agent . Acetaminophen . Amphotericin . Foscarnet . Concurrent Treatment : Allowed : Radiation therapy unlikely cause peripheral neuropathy use anticipate treatment acute intercurrent illness opportunistic infection . Transfusion anemia . Exclusion Criteria Coexisting Condition : Patients follow exclude : Active opportunistic infection require treatment unallowed drug . Symptomatic visceral Kaposi 's sarcoma ( KS ) , progression KS within month prior study entry , concurrent neoplasm KS , basal cell carcinoma skin , situ carcinoma cervix . History peripheral neuropathy significant sign symptom neurological disease , abnormality indicative peripheral neuropathy . Significant cardiac disease define history ventricular arrhythmia require medication , prior myocardial infarction , history angina ischemic change electrocardiogram . Significant liver disease define transaminase level history cirrhosis ascites . Significant renal disease define serum creatinine . Concurrent Medication : Excluded : Experimental drug include fluconazole , foscarnet . Immunomodulators include interferon , interleukin , systemic corticosteroid . Ganciclovir . Neurotoxic drug . Drugs could potentially cause peripheral neuropathy , include chloramphenicol , cisplatin , iodoquinol , dapsone , phenytoin , disulfiram , ethionamide , glutethimide , gold , hydralazine , isoniazid , metronidazole , vincristine , nitrofurantoin . Excluded within 4 week study entry : Drugs cause significant nephrotoxicity significant hepatotoxicity ( defined transaminase ) . Concurrent Treatment : Excluded : Transfusion dependent . Patients exclude unwilling unable sign inform consent . Prior Medication : Excluded : Zidovudine ( AZT ) . Dideoxycytidine ( ddC ) . Any nucleoside antiretrovirals . Positive antibody HIV use federally license ELISA test kit . Diagnosis AIDS AIDSrelated complex ( ARC ) . Active substance alcohol abuse .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 1992</verification_date>
	<keyword>Zalcitabine</keyword>
	<keyword>Drug Therapy , Combination</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>AIDS-Related Complex</keyword>
	<keyword>Zidovudine</keyword>
</DOC>